Cancers with a proficient MMR system, however, comprise the majority (80% to 85%) of colorectal cancers and adjuvant therapy decision in such patients should be addressed to other factors[19], for instance TYMS expression, which we found associated to therapy benefit in patients with pMMR tumours (Figure 5). The gene discussed is TYMS; the disease is cancer.